the feasibility of this technique has been extensively reported in breast cancer patients and other cancer types.10–17 A dose-finding study performed by our group previously demonstrated that NIR fluorescence using a dose of 500 μM ICG adsorbed to human serum albumin was most convenient.18 A follow-up double-blind randomized clinical trial demonstrated no advantages of premixing ICG with human serum albumin in comparison to ICG alone at a dose of 500 μM for NIR fluorescence SLN mapping.19 The gene discussed is ALB; the disease is breast cancer.